Evinacumab
As of the edition of 20 October 2026, Evinacumab is an antibody: marketed, first approved in 2021 (US); acts on ANGPTL3; US protection ends in 2033.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Antibody
- Brand name
- Evkeeza
- First approved
- 11 February 2021 (US)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Ultragenyx Pharmaceutical; 2 holders in all
- Registered trials
- 13, 1 stopped early
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2033.
US protection ends in 2033, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Regeneron. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Evinacumab.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ANGPTL3 | Angiopoietin-related protein 3 | Q9Y5C1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 5 | 3 | 1 | 1 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Regeneron | Originator and Lead sponsor of trials | 2021 to now |
| Ultragenyx Pharmaceutical | Applicant | 2021 to now |